Dual GLP-1/GIP receptor agonists, particularly tirzepatide, have demonstrated superior metabolic benefits compared to GLP-1 monotherapy in trials such as SURPASS-2 [9], with great reductions in glycated hemoglobin, body weight and insulin resistance. Here, GLP1R is linked to Insulin resistance.